Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial

Journal:

The Lancet

Published:

2026-02-07

DOI:

10.1016/s0140-6736(25)01948-8

Affiliations:

12

Authors:

19

Go to article

Institutions	Authors	Share
Merck & Co, United States of America (USA)	9.000000	0.47
Men's Health Foundation, United States of America (USA)	1.000000	0.05
Midway Immunology Research Center, United States of America (USA)	1.000000	0.05
North Texas Infectious Diseases Consultants (NTIDC), United States of America (USA)	1.000000	0.05
Triple O Research Institute PA, United States of America (USA)	1.000000	0.05
Orlando Immunology Center (OIC), United States of America (USA)	1.000000	0.05
Gordon E. Crofoot MD, PA, United States of America (USA)	1.000000	0.05
Mercer University Health Sciences Center, Mercer University, United States of America (USA)	1.000000	0.05
National Institute of Global Health and Medicine, Japan	1.000000	0.05
Royal Free London NHS Foundation Trust, United Kingdom (UK)	1.000000	0.05
Community Resource Initiative, United States of America (USA)	0.500000	0.03
Cambridge Health Alliance (CHA), United States of America (USA)	0.500000	0.03

Interested in Clinical Sciences?